LIMERICK, Ireland, Dec. 13, 2021 /CNW/ - kneat.com,
inc. (TSX: KSI) ("Kneat or the
Company") a leader in digitizing and
automating validation and quality processes, is pleased to announce
a global e-Validation study that details its partnership with life
sciences leader Merck Sharp & Dohme (MSD).
This new study highlights how the Kneat platform is supporting
MSD's strategy for continuous improvement of its quality management
systems. Kneat's platform enabled end-to-end digitalization
of seven key validation work processes across twenty-seven sites
throughout the COVID-19 pandemic.
"From an efficiency perspective…we were able to demonstrate more
than 50% cycle time reduction during execution, which was huge for
us," said Inna Ben-Anat, former
Executive Director, QMS Technology Transfer &
Commercialization, MSD.
With the use of Kneat's platform, MSD saw significant results.
Process simplification was streamlined down from fifteen to eight
steps in their Manufacturing & Research divisions, while the
number of systems utilized was reduced from five to two.
"Kneat is an excellent partner, not just because of the
technical support, but because we felt as though we were part of
the team…..Kneat partnered with us to solve all potential
challenges", Ms. Ben-Anat added.
The study demonstrates MSD's culture of continuous improvement
including its goal for end-to-end digitalization of all validation
and qualification activity in Kneat by 2022. It offers a
testament to the proficiency of Kneat's software, covering its user
experience, functional capabilities, and the Company's robust
relationship management.
"MSD is a global leader at the forefront of medical research and
we appreciate that they have placed their confidence in Kneat,"
said Eddie Ryan, Chief Executive
Officer of Kneat. "We look forward to supporting MSD in their
digitalization goals in the coming years."
Read the full success story on Kneat's website here.
About Kneat
Kneat, a Canadian company with operational headquarters in
Limerick, Ireland, develops and
markets the next generation Kneat Gx software platform. Multiple
business work processes can be configured on the platform from
equipment to computer system validation, through to quality
document management. Kneat's software allows users to author,
review, approve, execute testing online, manage any exceptions and
post approve final deliverables in a controlled FDA 21 CFR Part 11/
Eudralex Annex 11 compliant platform. Macro and micro report
dashboards enable powerful oversight into all systems, projects and
processes globally. Customer case studies are reporting
productivity improvements in excess of 100% and a higher data
integrity and compliance standard. For more information visit
www.kneat.com.
Cautionary and Forward-Looking Statements
Except for the statements of historical fact contained herein,
certain information presented constitutes "forward-looking
information" within the meaning of applicable Canadian securities
laws. Such forward-looking information includes, but is not limited
to, the relationship between Kneat and the customer, Kneat's
business development activities, the use and implementation
timelines of Kneat's software within the customer's validation
processes, the ability and intent of the customer to scale the use
of Kneat's software within the customer's organization and the
compliance of Kneat's platform under regulatory audit and
inspection. While such forward-looking statements are expressed by
Kneat, as stated in this release, in good faith and believed by
Kneat to have a reasonable basis, they are subject to important
risks and uncertainties. As a result of these risks and
uncertainties, the events predicted in these forward-looking
statements may differ materially from actual results or events.
These forward-looking statements are not guarantees of future
performance, given that they involve risks and uncertainties. The
forward-looking information in this press release does not include
a full assessment or reflection of the unprecedented impacts of the
COVID-19 pandemic occurring since the first quarter of 2020 and the
ongoing and developing resulting indirect global and regional
economic impacts. This has resulted in significant economic
uncertainty and even though the company has to date experienced no
significant impact to its operations, any potential impact on our
future is difficult to understand or measure at this time. Kneat
does not undertake any obligation to release publicly revisions to
any forward-looking statement, except as may be required under
applicable securities laws. Investors should not assume that any
lack of update to a previously issued forward-looking statement
constitutes a reaffirmation of that statement. Continued reliance
on forward-looking statements is at an investors' own risk.
SOURCE kneat.com, inc.